Study protocol for The Heart Watch Study - Prognostic performance of smartwatch 12-lead ECG with advanced ECG analysis in consumer self-screening for cardiovascular disease

Zaidon S Al-Falahi MBBCh[1], Todd T Schlegel MD[2,3], Rebecca Kozor MBBS PhD[1],

Thomas Lindow MD PhD[1,4], Martin Ugander MD PhD[1,2§]

[1]Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia

[2]Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

[3]Nicollier-Schlegel SARL, Trélex, Switzerland

[4]Respiratory Medicine, Allergology, and Palliative Medicine, Clinical Sciences, Lund University, Lund, Sweden; Department of Clinical Physiology, Research and Development, Region Kronoberg, Vaxjo, Sweden

§ denotes corresponding author, martin.ugander@gmail.com

Abstract

Background: It is now possible to acquire a fully diagnostic standard 12-lead electrocardiography (ECG) using a smartwatch, a smartphone app, and no additional hardware. This study aims to evaluate the predictive performance of advanced ECG (A-ECG) analysis applied to a smartwatch 12-lead ECG (SWECG) acquired using an Apple Watch in identifying cardiovascular risks among asymptomatic adults performing consumer self-screening in the general population. **Methods and Design**: The Heart Watch Study is a prospective, Australia-wide observational cohort study. We aim to recruit 30,000 asymptomatic participants aged 20-79 years without prior known cardiovascular disease. Participants will enrol and consent electronically, and download a dedicated study iPhone app that enables a directed 12-lead SWECG acquisition using their Apple Watch. The recordings will undergo both conventional and A-ECG analysis. Follow-up will be performed through linkage with administrative health datasets in Australia, including hospital visits and mortality records. The primary combined endpoint is all-cause mortality, hospitalization for cardiovascular causes and incident cardiovascular disease (arrythmia, ischemic heart disease, heart failure) as predicted by A-ECG analysis. **Conclusion**: This study evaluates the feasibility of performing a fully diagnostic standard 12-lead SWECG using only a smartwatch and a smartphone application, and addresses the prognostic value of A-ECG machine-learning based analysis in consumer self-screening in a large, diverse and apparently healthy population.

Background

Advanced ECG analysis of smartwatch 12-lead ECGs

Cardiovascular disease (CVD) benefits from early detection and intervention, yet presymptomatic features are difficult to detect and generally go unnoticed with adverse prognostic implications. The standard 12-lead ECG is a cornerstone of cardiac diagnostics worldwide for millions of patients every day [1]. However, population screening for CVD using conventional ECG acquisition and interpretation is currently not recommended due to its cost and suboptimal sensitivity and specificity for pre-symptomatic disease [2]. Our group has developed a validated method for recording accurate standard 12-lead ECG recordings using a smartwatch and a dedicated smartphone app with no additional hardware [3]. Furthermore, by incorporating advanced ECG analysis (A-ECG) through transparent and quantifiable vectorcardiographic and waveform complexity measures, the accuracy of ECG for detecting CVD can be substantially improved [4-7]. Using A-ECG software (Advanced ECG Systems, Sydney, Australia) to measure these features, and applying multivariable machine learning, several disease-specific risk scores can be automatically presented with improved accuracy compared to conventional ECG interpretation [4].

Enabling the acquisition of a fully diagnostic, clinical-grade standard 12-lead ECG using increasingly ubiquitous consumer technology, coupled with A-ECG analysis could address both issues of access and accuracy and potentially transform population-level cardiovascular prevention.

Rationale for Current Study

Smartwatch 12-lead ECG (SWECG) has the potential to extend current diagnostic applications of ECG diagnostics to the community, including baseline acquisition and storage for later comparisons, serial acquisitions in established CVD, telehealth applications, and rare

disease screening such as some ion channelopathies. Attempts have been made to use

smartphones or smartwatches to obtain a multi-lead ECG through either sequential recording

or via interpolation using deep neural networks, but the resultant ECGs are inherently not

identical to the standard 12-lead ECG [7-9]. We have developed a method for calculation of

all leads present in the standard 12-lead ECG by accurately time-aligning sequentially

recorded leads, which allows for correct calculation of Wilson's central terminal, and in turn

is essential for calculating correct chest leads. Taken together, the SWECG approach allows

for smartwatch ECG recording while preserving the accuracy of standard 12-lead ECG.

However, before clinical implementation, the association between pathological findings by

12-lead SWECG with A-ECG analysis and CVD outcomes remains to be determined.

Furthermore, the dose-response relationship between activity levels and health outcomes has

been recognized by the World Health Organization (WHO) as an area in need of further

research [10]. The Heart Watch Study will contribute to this research area by providing

activity data from Apple Health paired with A-ECG analysis and long-term outcomes.

Finally, The A-ECG Heart Age is another prognostic metric of accelerated cardiovascular

ageing that can be intuitively communicated to the public, potentially providing strong

incentive for lifestyle interventions [11, 12]. A-ECG Heart Age will be calculated from the

12-lead SWECG for all participants and validated against health outcomes. This evidence

will be used to design further interventional studies to slow down or reverse accelerated

cardiovascular ageing.

Objectives

Primary Objective

To prospectively assess the prognostic performance of A-ECG risk scores from 12-lead

SWECG in a broad and asymptomatic consumer self-screening population for predicting

cardiovascular events at 2 years.

Secondary Objectives

- **Prognostic value of A-ECG Heart Age**: To explore the prognostic association of A-
ECG Heart Age as derived from the 12-lead Apple Watch ECG, comparing it against
conventional age and health markers for cardiovascular risk prediction.

- **Physical activity and cardiovascular health**: To investigate the impact of
objectively measured physical activity on cardiovascular health outcomes, utilizing
the data integration capabilities of smartwatches.

- **Changes in A-ECG and physical activity**: To determine whether changes in
physical activity over time correlate with changes in A-ECG Heart Age, providing
insights into dynamic health status influenced by lifestyle factors.

- **Real-world efficacy of A-ECG and AI-ECG**: To compare the real-world diagnostic
efficacy of SWECG A-ECG and AI-ECG analysis and validate their efficacy in a
consumer self-screening setting.

- **Screening and referral efficacy**: To assess the proportion of the study population
that exhibits ECG and A-ECG findings necessitating a recommendation for further
medical evaluation, particularly for relatively rare cardiac conditions, e.g ion
channelopathies, in an asymptomatic screening context.

- **Long-term outcomes of A-ECG and activity scores**: To evaluate the long-term
health outcomes associated with A-ECG scores and physical activity metrics beyond
the initial two-year follow-up period.

- **Compliance with WHO physical activity guidelines**: To quantify the proportion of the study population adhering to the World Health Organization's physical activity guidelines and to examine the association of compliance with cardiovascular health outcomes.

Methods

Study design

A prospective, large-scale, observational cohort study with outcome ascertainment at 2 years via routinely collected health administrative datasets in Australia.

The study aims to recruit 30,000 participants throughout Australia. No physical visits are required, enrolment and data collection are conducted entirely online.

Eligibility Criteria

Access to an ECG-enabled Apple Watch series 4 or later and a paired and compatible iPhone.

Inclusion Criteria

Asymptomatic individuals 20-80 years of age without known CVD. Participants will be included according to an age- and sex-stratification encompassing 2500 individuals per decade of age and sex.

Exclusion Criteria

Known heart disease including arrhythmia, cardiomyopathy, ischemic heart disease, congenital heart disease, previous cardiac interventions, e.g. percutaneous coronary intervention, coronary artery by-pass grafting, implanted cardiac devices, and bundle branch blocks.

Recruitment

Participants will be recruited from the general population through media campaigns (social

media, and conventional media). Participants will complete an online screening questionnaire

and provide baseline information on age, sex, identification information, and medical history

and if they meet the inclusion criteria, will be issued with a unique identification code to

activate the free study smartphone app downloadable from the Apple App Store. The app will

enable the participants to self-record the smartwatch 12-lead ECG and transmit it, along with

Apple Health data, to secure research servers. All consent is provided electronically.

Data Collection

In addition to the smartwatch 12-lead ECG, physical activity and Apple Health data from the

preceding 12 months will be extracted. All ECGs will undergo manual ECG interpretation by

cardiac technicians supervised by a board-certified cardiologist. Pre-determined criteria for

triggering referral for further medical evaluation based on traditional 12-lead ECG findings

rely on international recommendations for ECG interpretation in athletes [13]. Subsequently,

all participants, including those meeting criteria recommended to have further medical

evaluation, will undergo A-ECG analysis.

Smartwatch 12-Lead ECG acquisition method

Study duration and follow-up

At 2 years, participant data will be cross-linked with data from the National Death Index and

health administrative datasets on routinely collected health data, from which data on incident

major cardiovascular diagnoses, all-cause hospitalisation, and death, including cause of death,

will be retrieved. Physical activity records will be examined separately.

After 12 months, A subset of participants (n=1000) will be contacted electronically (by SMS

and/or email) and asked to perform an additional 12-lead SWECG recording, and to share

physical activity data of the preceding 12 months. The subset will be selected based on age,

sex, A-ECG Heart Age, availability of physical activity levels in the initial extraction, and the

quality of the 12-lead ECG recording. A-ECG Heart Age is a validated estimate of

accelerated cardiovascular aging expressed in years of healthy human ageing, while the Heart

Age gap is the difference between Heart Age and chronological age [11, 12]. This sub-

analysis will provide information on changes in ECG Heart age and physical activity levels.

Collection of Apple Health Information

For purpose of the study, the study app will request to read and share permissions that the

participant can individually authorize to the following data.

-    **Activity data** including steps, walking and running distance, active energy, resting energy,

standing time, exercise time, flights climbed, workouts, derived cardio fitness in VO2

max, cycling distance, swimming distance and strokes, wheelchair pushes and distance for

wheelchair-bound individuals if applicable.

-    **Body measurements including** height, weight, body mass index (BMI), body fat

percentage, lean body mass, waist circumference, body temperature, and electrodermal

activity.

-    **Cardiac data** including mean heart rate, heart rate at rest, and walking or exercising, heart

rate variability, ECGs, blood pressure measurements, and notifications about low, high

and irregular heart rate.

-    **Mobility data** including double support time, step length, walking asymmetry, walking

speed, walking steadiness, six-minute walk distance, speed on stairs, falls and

notifications.

-   **Sleep data** including sleep patterns, schedule, and hours.

Hardware and Software Versions

An ECG-enabled Apple Watch Series 4 or later (not Apple Watch SE) and a paired iPhone

are required for enrolment. The study app track the iPhone and Apple Watch versions as well

as the iOS and WatchOS versions to enable retrospective analysis of the potential impact on

ECG data related to software version.

Study visits and procedures schedule

The study does not include any in-person visits for study participants. Recruitment and

consent will be performed entirely online, and participants will only be contacted in the

following circumstances:

1. Detection of a major ECG abnormality according to pre-set criteria on their 12-lead

ECG. The participant will then receive written information with the recommendation to

seek evaluation from a primary care doctor as detailed further below.

2. Possible request for a repeat ECG recording if initial ECG was unsuitable for analysis

due to poor quality, significant artifacts, or incomplete/incorrect recording.

3. Contact to request participation in a follow-up study at 12 months for another self-

recorded ECG recording and extraction of activity data as described earlier.

All contact will be written via SMS and/or email to the contact information supplied by the

participant at enrolment.

Potential study risks

No adverse events are expected from recording the ECG. Participating in a study aiming to

identify people at risk of CVD may lead to a misconception from the participant that they are

being monitored for disease, which may affect their decision on whether to seek medical

assistance in the occurrence of cardiac symptoms. This risk will be reduced by thorough

participant information to the study participants.

Data research and collection of personal information is inherently associated with risk of

spread of personal information should a security breach occur. Anonymized data will be

stored using University of Sydney's data collection and storage infrastructure.

ECG abnormalities to potentially trigger further evaluation

This is an observational cohort study to assess the prognostic performance of novel

technology (A-ECG analysis of 12-lead SWECG) to detect subclinical cardiovascular disease

in a population without known heart disease. There is no available evidence to support

clinical decision making in such a circumstance.

This study does not interfere with the current standards of care. The incidental detection of

ECG abnormalities requiring further clinical work up on screening of an apparently healthy

population is a debatable [14-18].

In an Australian validation of an earlier version of the international consensus (Seattle

criteria), out of 1197 Australian athletes screened, 4.5% were found to have abnormalities

and only 0.3% had true underlying life-threatening abnormalities, yielding a false positive

rate of 4.2%. The International Consensus of 2018 refined the Seattle Criteria, lowering that

percentage further. In cases of 12-lead ECG findings that existing guidelines suggest that

medical attention would be appropriate (as detailed in Table 1 below), the participant will

receive a notification by text and/or email recommending them to visit their primary care

physician, along with a referral letter containing the Apple Watch-derived 12-lead ECG and

an outline of the findings (Table 1).

STATISTICAL METHODS

Sample size calculations

Sample size estimation is based on an expected annual rate of 0.02 cardiovascular events (at mean follow-up of 2 years) in an asymptomatic general population to detect a hazard ratio of 1.8 (A-ECG pos/neg; proportion 0.05) at α 0.05 and power 0.9, a sample size 27674 allowing for a censoring rate of 30% [19]. A sample size of 30000 study participants would thus be adequate to meet the primary objective.

For the secondary endpoint of evaluating the correlation between changes in ECG Heart Age and activity levels, a sample size of 1000 participants is estimated. This was based on an expected correlation at r=0.15 (α 0.05, power 0.9) requiring 463 subjects and thus allowing for a combined 50% rate of dropouts to repeated ECG recording and ECG abnormalities not suitable for the estimation of ECG Heart Age.

Analysis Plan

ECGs and disease prediction

Continuous variables will be described using mean and standard deviation (SD), or medians and interquartile range as appropriate. Proportional differences between groups will be assessed using the χ2 test. Comparison of group means will be performed using Student's t test.

Time-to-event data will be visually described using Kaplan-Meier event-free survival graphs. The association between smartwatch A-ECG scores and outcomes will be assessed using Cox proportional hazards regression models, unadjusted and adjusted for confounders (age, sex, BMI, smoking, hypertension, diabetes). Hazard ratios (HRs) will be presented with 95 %

confidence intervals (CIs) and the assumption of proportional hazards will be confirmed

using Schoenfeld's residuals.

ECG Heart Age

The association of ECG Heart Age and cardiovascular outcomes will be assessed using Cox

proportional hazards regression models. The correlation between ECG Heart Age and activity

levels will be studied using linear regression.

Activity levels and cardiovascular events

The association between activity levels and cardiovascular outcomes will be assessed using

Cox proportional hazards regression models, unadjusted and adjusted for confounders (age,

sex and BMI).

Ethical considerations

The Northern Sydney Local Health District Human Research Ethics Committee approved the

study (approval number 2022/ETH01269).

Discussion

The ECG remains a foundational aspect of cardiovascular assessment, yet its acquisition

requires specialized equipment operated by specialized personnel in a clinical setting.

Enabling the acquisition of a fully diagnostic standard 12-lead ECG using just a smartwatch,

a smartphone app, and no additional hardware is a first-of-its-kind opportunity, allowing

clinical-grade ECG diagnostics using consumer-grade wearables.

Furthermore, conventional interpretation relies on visual waveform assessment to detect

abnormalities of rate, rhythm or other pathologies such as myocardial ischemia. Early ECG

changes of disease can be subtle and undiscernible to the unaided human eye [20]. The ECG

harbours a wealth of latent information that can only be extracted with advanced

mathematical analyses and computational techniques [20]. Thus, analysing 12-lead SWECG

using automated A-ECG or AI-ECG could address the diagnostic yield and resource scaling

limitations that thus far have precluded effective population screening with ECGs. These

techniques offer superior diagnostic accuracy to the traditional 12-lead ECG analysis [4].

This study aims to employ these recent clinical advancements and assess their real-world

performance to address multiple gaps in our evidence base regarding population-level

cardiovascular screening.

A-ECG Heart Age

The A-ECG Heart Age is a prediction of an individual's age from their ECG and is

concordant with chronological age in healthy individuals but shows increasing deviation with

cardiovascular risk factors and disease [11, 12]. It is a validated prognostic marker that can be

intuitively communicated to the general public to spur preventive action. This study will

enable prospective validation of the prognostic accuracy of A-ECG Heart Age as well as

similar estimations based on neural network AI methods.

Activity levels and Cardiovascular Events

CVD is substantially influenced by modifiable behavioural risk factors and physical activity

is recognized as a crucial preventive measure that can reduce mortality and cardiovascular

risk by 75% [21, 22]. Despite the potential to prevent 5 million deaths annually through

increased physical activity, global participation remains low with most adults failing to meet

recommended levels. The reliability of self-reported activity measures often varies,

prompting an increased use of activity trackers and smartwatches for more accurate

assessments [23, 24]. Studying the association between physical activity, cardiovascular risk

factors, Heart Age and outcomes will provide needed evidence for future interventional

preventive studies.

However, accurately quantifying physical activity in the public is challenging. Wearable

devices may enable the collection of objectively measured physical activity parameters. Few

cross-sectional studies report increased physical activity levels in individuals who own such

devices in adolescents and older adults [25, 26]. However, a limited number of studies report

on habitual levels of activity in individuals who own an activity tracker and the associated

health outcomes [27, 28]. Therefore, collecting physical activity data from individuals who

already own a smartwatch will allow for accurate assessment of activity levels. This can be

further assessed to examine the association between activity levels and the risk of

cardiovascular events.

Summary

This observational cohort study aims to evaluate the association between findings obtained

from a 12-lead SWECG, combined with A-ECG analysis, in detecting cardiovascular

morbidity and mortality among a large cohort of asymptomatic adults across Australia. This

study explores the potential of consumer-grade technology to facilitate early detection and

prevention in cardiovascular health, potentially allowing for community-based health

monitoring and new preventive strategies.

Disclosures

TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation

consultancy using software that can quantify the advanced ECG measures used in the current

study. TTS and MU are founders of Advanced ECG Systems, a company that is developing

commercial applications of advanced ECG technology used in the current study. RK has a

financial interest in Advanced ECG Systems through being married to MU.

REFERENCES

1. Kligfield, P., et al., *Recommendations for the Standardization and Interpretation of the Electrocardiogram. Part I: The Electrocardiogram and Its Technology. A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology.* Circulation, 2007.

2. Maron, B.J., et al., *Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 Years of Age): a scientific statement from the American Heart Association and the American College of Cardiology.* Circulation, 2014. **130**(15): p. 1303-34.

3. Curtis T, S.T., Ugander M, *Smartwatch 12-lead ECG: Accuracy of standard 12-lead electrocardiography from serial single lead acquisitions*, in *Digital Health Week 2021*. 2021: University of Sydney.

4. Schlegel, T.T., et al., *Accuracy of advanced versus strictly conventional 12-lead ECG for detection and screening of coronary artery disease, left ventricular hypertrophy and left ventricular systolic dysfunction.* BMC Cardiovasc Disord, 2010. **10**: p. 28.

5. *Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.* British Medical Journal, 1991. **303**(6807): p. 893.

6. Hughes, R.K., et al., *Accurate diagnosis of apical hypertrophic cardiomyopathy using explainable advanced electrocardiogram analysis.* EP Europace, 2024. **26**(4): p. euae093.

7. Maanja, M., et al., *An electrocardiography score predicts heart failure hospitalization or death beyond that of cardiovascular magnetic resonance imaging.* Scientific Reports, 2022. **12**(1): p. 18364.

8. Lindow, T. and O. Pahlm, *Smartphone 12-lead ECG-Exciting but must be handled with care.* Am Heart J, 2020. **226**: p. 267-268.

9. Muhlestein, J.B., et al., *Smartphone ECG for evaluation of STEMI: results of the ST LEUIS Pilot Study.* J Electrocardiol, 2015. **48**(2): p. 249-59.

10. Bull, F.C., et al., *World Health Organization 2020 guidelines on physical activity and sedentary behaviour.* Br J Sports Med, 2020. **54**(24): p. 1451-1462.

11. Lindow, T., et al., *Heart age gap estimated by explainable advanced electrocardiography is associated with cardiovascular risk factors and survival.* European Heart Journal - Digital Health, 2023: p. ztad045.

12. Lindow, T., et al., *Heart age estimated using explainable advanced electrocardiography.* Scientific Reports, 2022. **12**(1): p. 9840.

13. Sharma, S., et al., *International recommendations for electrocardiographic interpretation in athletes.* European Heart Journal, 2018. **39**(16): p. 1466-1480.

14. Arne, L., et al., *The International Olympic Committee (IOC) Consensus Statement on periodic health evaluation of elite athletes March 2009.* British Journal of Sports Medicine, 2009. **43**(9): p. 631.

15. Maron, B.J., et al., *Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update.* Circulation, 2007. **115**(12): p. 1643-1655.

16. Uberoi, A., et al., *Interpretation of the Electrocardiogram of Young Athletes.* Circulation, 2011. **124**(6): p. 746-757.

17. Jonathan, A.D., et al., *Electrocardiographic interpretation in athletes: the 'Seattle Criteria'.* British Journal of Sports Medicine, 2013. **47**(3): p. 122.

370   18.   Sheikh, N., et al., *Comparison of Electrocardiographic Criteria for the Detection of*
371   *Cardiac Abnormalities in Elite Black and White Athletes.* Circulation, 2014. **129**(16):
372   p. 1637-1649.

373   19.   Schoenfeld, D.A., *Sample-size formula for the proportional-hazards regression*
374   *model.* Biometrics, 1983. **39**(2): p. 499-503.

375   20.   Goldberger, A.L., et al., *PhysioBank, PhysioToolkit, and PhysioNet.* Circulation,
376   2000. **101**(23): p. e215-e220.

377   21.   Bian, Z., et al., *Genetic predisposition, modifiable lifestyles, and their joint effects on*
378   *human lifespan: evidence from multiple cohort studies.* BMJ Evidence-Based
379   Medicine, 2024: p. bmjebm-2023-112583.

380   22.   Kraus, W.E., et al., *Physical Activity, All-Cause and Cardiovascular Mortality, and*
381   *Cardiovascular Disease.* Med Sci Sports Exerc, 2019. **51**(6): p. 1270-1281.

382   23.   Evenson, K.R., F. Wen, and A.H. Herring, *Associations of Accelerometry-Assessed*
383   *and Self-Reported Physical Activity and Sedentary Behavior With All-Cause and*
384   *Cardiovascular Mortality Among US Adults.* Am J Epidemiol, 2016. **184**(9): p. 621-
385   632.

386   24.   Henson, J., et al., *Associations of objectively measured sedentary behaviour and*
387   *physical activity with markers of cardiometabolic health.* Diabetologia, 2013. **56**(5):
388   p. 1012-20.

389   25.   Ng, K., J. Tynjälä, and S. Kokko, *Ownership and Use of Commercial Physical*
390   *Activity Trackers Among Finnish Adolescents: Cross-Sectional Study.* JMIR Mhealth
391   Uhealth, 2017. **5**(5): p. e61.

392   26.   Li, L., et al., *Factors Associated with Older Adults' Long-Term Use of Wearable*
393   *Activity Trackers.* Telemed J E Health, 2020. **26**(6): p. 769-775.

394   27.   Menai, M., et al., *Cross-Sectional and longitudinal associations of objectively-*
395   *measured physical activity on blood pressure: evaluation in 37 countries.* Health
396   Promot Perspect, 2017. **7**(4): p. 190-196.

397   28.   Shin, G.D., *Investigating the impact of daily life context on physical activity in terms*
398   *of steps information generated by wearable activity tracker.* Int J Med Inform, 2020.
399   **141**: p. 104222.

402   **Tables**

404   Table 1: Smartwatch 12-lead ECG findings to trigger referral to the primary care doctor

ECG abnormality	Definition
T wave inversion	≥1 mm in depth in two or more contiguous leads; excludes leads aVR, III and V1
Anterior	V2-V4(excluding black athletes with J-point elevation and convex ST segment elevation followed by T-wave inversion in V2-V4; athletes < age 16 with T-wave inversion in V1-V3; and biphasic T waves in V3 only)
Lateral	I and aVL, V5 and/or V6 (only one lead of TWI required in V5 or V6)
Inferolateral	II and aVF, V5-V6, I and aVL
Inferolateral Inferior	II and aVF, V5-V6, I and aVL II and aVF
Inferior ST segment depression	II and aVF ≥0.5 mm in depth in two or more contiguous leads
Pathological Q waves	Q/R ratio ≥0.25 or ≥40 ms in duration in two or more leads (excluding III and aVR)
Complete left bundle branch block	QRS ≥120 ms, predominantly negative QRS complex in lead V1 (QS or rS) and upright notched or slurred R wave in leads I and V6
Non-specific intraventricular conduction delay	Any QRS duration ≥140 ms
Epsilon wave	Distinct low amplitude signal (small positive deflection or notch) between the end of the QRS complex and onset of the T wave in leads V1-V3
Ventricular pre-excitation	PR interval <120 ms with a delta wave (slurred upstroke in the QRS complex) and wide QRS (≥120 ms)
Prolonged QT interval*	QTc ≥470 ms (male)
Prolonged QT interval*	QTc ≥480 ms (female)

Brugada type 1 pattern	QTc ≥500 ms (marked QT prolongation)
	Coved pattern: initial ST elevation ≥2 mm (high take-off) with downsloping ST segment elevation followed by a negative symmetric T wave in ≥1 leads in V1-V3
Profound sinus bradycardia	<30 beats per minute or sinus pauses ≥3 s
Profound 1° atrioventricular block	≥400 ms
Mobitz type II 2° atrioventricular block	Intermittently non-conducted P waves with a fixed PR interval
3° atrioventricular block	Complete heart block
Atrial tachyarrhythmias	Supraventricular tachycardia (>100bpm), atrial fibrillation, atrial flutter
Premature ventricular contractions	≥2 premature ventricular contractions per 10 s tracing
Ventricular arrhythmias	Couplets, triplets and non-sustained ventricular tachycardia (frequent)